Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Compugen Ltd. (NASDAQ: CGEN).

Full DD Report for CGEN

You must become a subscriber to view this report.


Recent News from (NASDAQ: CGEN)

Compugen Ltd. (CGEN) CEO Dr. Anat Cohen-Dayag on Q3 2018 Results - Earnings Call Transcript
Compugen Ltd. (SUMR) Q3 2018 Results Earnings Conference Call November 07, 2018 08:30 AM ET Executives Elana Holzman - Investor Relations Dr. Anat Cohen-Dayag - President & CEO Dr. Henry Adewoye - Chief Medical Officer Ari Krashin - CFO and COO Analysts Konstantinos A...
Source: SeekingAlpha
Date: November, 07 2018 22:50
Compugen up 2% on Q3 results
Compugen ( CGEN ) Q3 results : Revenues: $7.8M. More news on: Compugen Ltd., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: November, 07 2018 09:05
Compugen beats by $0.14, beats on revenue
Compugen (NASDAQ: CGEN ): Q3 GAAP EPS of -$0.05 beats by $0.14 . More news on: Compugen Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: November, 07 2018 07:04
Compugen Reports Third Quarter 2018 Results
HOLON, Israel , Nov. 7, 2018 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the third quarter ended September 30, 2018 . "The last few months have been high...
Source: PR Newswire
Date: November, 07 2018 07:00
Compugen Third Quarter 2018 Conference Call Scheduled for Wednesday, November 7, 2018 at 8:30 AM ET
HOLON, Israel , Oct. 24, 2018 /PRNewswire/ --  Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its third quarter 2018 financial results on Wednesday, November 7...
Source: PR Newswire
Date: October, 24 2018 07:15
Compugen Ltd. (CGEN) Compugen and Bristol-Myers Squibb Clinical Collaboration and Equity Investment Conference Call (Transcript)
Compugen Ltd. (CGEN) Bristol-Myers Squibb Clinical Collaboration and Equity Investment Conference Call October 11, 2018 08:30 AM ET Executives Elana Holzman - Investor Relations and Corporate Communications Anat Cohen-Dayag - President and CEO Kirk Christoffersen - Senior Vice P...
Source: SeekingAlpha
Date: October, 12 2018 18:40
Premarket Gainers as of 9:05 am (10/11/2018)
SPEX +34%  on merger agreement with CBM BioPharma. More news on: Spherix Incorporated, Compugen Ltd., Turtle Beach Corporation, Stocks on the move, , Top stock market news, Read more ...
Source: SeekingAlpha
Date: October, 11 2018 09:15
Compugen up 18% premarket on collaboration with Bristol-Myers Squibb team in study of doublet therapy in solid tumors
Thinly traded micro cap Compugen (NASDAQ: CGEN ) is up  18%  premarket on light volume on the heels of its announced collaboration with Bristol-Myers Squibb (NYSE: BMY ) evaluating the combination of COM701, an anti-PVRIG antibody, and Opdivo (nivolumab) in patients with advanced...
Source: SeekingAlpha
Date: October, 11 2018 07:23
Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors
NEW YORK and HOLON, Israel , Oct. 11, 2018 /PRNewswire/ --  Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen's COM701, an invest...
Source: PR Newswire
Date: October, 11 2018 06:59
Compugen Announces Clinical Milestone Payment in Cancer Immunotherapy Collaboration With Bayer Following Dosing of First Patient in BAY 1905254 Phase 1 Trial
HOLON, Israel , Sept. 20, 2018 /PRNewswire/ --   Compugen Ltd.   (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, was informed that Bayer AG dosed the first patient in the Phase 1 clinical trial of BAY 1905254, a firs...
Source: PR Newswire
Date: September, 20 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-183.303.253.453.25270,528
2018-05-173.303.253.453.25270,528
2017-02-024.654.654.704.6531,790
2017-02-014.754.704.854.6550,165
2017-01-314.604.754.804.6057,241

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1211,58636,54731.7016Cover
2018-12-112,81024,09111.6641Cover
2018-12-108,54449,09017.4048Cover
2018-12-075,82223,36524.9176Cover
2018-12-0611,84922,66452.2812Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CGEN.


About Compugen Ltd. (NASDAQ: CGEN)

Logo for Compugen Ltd. (NASDAQ: CGEN)

Not available

 

Contact Information

 

 

Current Management

  • Alex Kotzer / President, CEO

Current Share Structure

  • Market Cap: $171,831,785 - 05/11/2018
  • Issue and Outstanding: 51,293,070 - 12/31/2017

 


Recent Filings from (NASDAQ: CGEN)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 09 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 02 2018
Annual and transition report of foreign private issuers under sections 13 or 15(d)
Filing Type: 20-FFiling Source: edgar
Filing Date: March, 27 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 14 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 21 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 06 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: January, 31 2018

 

 


Daily Technical Chart for (NASDAQ: CGEN)

Daily Technical Chart for (NASDAQ: CGEN)


Stay tuned for daily updates and more on (NASDAQ: CGEN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CGEN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CGEN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CGEN and does not buy, sell, or trade any shares of CGEN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/